These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16973126)

  • 1. Identification of human alpha-synuclein specific single chain antibodies.
    Maguire-Zeiss KA; Wang CI; Yehling E; Sullivan MA; Short DW; Su X; Gouzer G; Henricksen LA; Wuertzer CA; Federoff HJ
    Biochem Biophys Res Commun; 2006 Nov; 349(4):1198-205. PubMed ID: 16973126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.
    Emadi S; Liu R; Yuan B; Schulz P; McAllister C; Lyubchenko Y; Messer A; Sierks MR
    Biochemistry; 2004 Mar; 43(10):2871-8. PubMed ID: 15005622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing antibody specificity to different protein morphologies by AFM.
    Wang MS; Zameer A; Emadi S; Sierks MR
    Langmuir; 2009 Jan; 25(2):912-8. PubMed ID: 19090748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies.
    Barkhordarian H; Emadi S; Schulz P; Sierks MR
    Protein Eng Des Sel; 2006 Nov; 19(11):497-502. PubMed ID: 16984950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlling the mass action of alpha-synuclein in Parkinson's disease.
    Kim C; Lee SJ
    J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity.
    Emadi S; Barkhordarian H; Wang MS; Schulz P; Sierks MR
    J Mol Biol; 2007 May; 368(4):1132-44. PubMed ID: 17391701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
    Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
    Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of alpha-synuclein following methamphetamine: is it good or bad?
    Mauceli G; Busceti CI; Pellegrini A; Soldani P; Lenzi P; Paparelli A; Fornai F
    Ann N Y Acad Sci; 2006 Aug; 1074():191-7. PubMed ID: 17105917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of a monoclonal antibody, against human α-synuclein, in a subpopulation of C57BL/6J mice, presenting a deletion of the α-synuclein locus.
    Mougenot AL; Bétemps D; Hogeveen KN; Kovacs GG; Chouaf-Lakhdar L; Milhavet O; Lehmann S; Legastelois S; Pin JJ; Baron TG
    J Neurosci Methods; 2010 Oct; 192(2):268-76. PubMed ID: 20709102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms.
    Halliday GM; McCann H
    Exp Neurol; 2008 Jan; 209(1):12-21. PubMed ID: 17706644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective detection, quantification, and subcellular location of alpha-synuclein aggregates with a protein aggregate filtration assay.
    Kramer ML; Behrens C; Schulz-Schaeffer WJ
    Biotechniques; 2008 Mar; 44(3):403-11. PubMed ID: 18361794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tilted properties of the 67-78 fragment of alpha-synuclein are responsible for membrane destabilization and neurotoxicity.
    Crowet JM; Lins L; Dupiereux I; Elmoualija B; Lorin A; Charloteaux B; Stroobant V; Heinen E; Brasseur R
    Proteins; 2007 Sep; 68(4):936-47. PubMed ID: 17554782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry.
    Mirzaei H; Schieler JL; Rochet JC; Regnier F
    Anal Chem; 2006 Apr; 78(7):2422-31. PubMed ID: 16579629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between metals and alpha-synuclein--function or artefact?
    Brown DR
    FEBS J; 2007 Aug; 274(15):3766-74. PubMed ID: 17617226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microarray expression analysis of human dopaminergic neuroblastoma cells after RNA interference of SNCA--a key player in the pathogenesis of Parkinson's disease.
    Häbig K; Walter M; Stappert H; Riess O; Bonin M
    Brain Res; 2009 Feb; 1256():19-33. PubMed ID: 19135032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Frequency of the IVS4+66A-G polymorphism in the alpha-synuclein gene in patients with Parkinson's disease in north-western Mexico].
    Ramírez-Jirano LJ; Ruiz-Sandoval JL; Jiménez-Gil FJ; Ramírez-Vega J; Vargas-Frutos E; Gallegos-Arreola MP
    Rev Neurol; 2007 Jan 1-15; 44(1):15-7. PubMed ID: 17199224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation.
    Martinez Z; Zhu M; Han S; Fink AL
    Biochemistry; 2007 Feb; 46(7):1868-77. PubMed ID: 17253773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease.
    Bharathi ; Rao KS
    Biochem Biophys Res Commun; 2007 Jul; 359(1):115-20. PubMed ID: 17531952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The aggregation and fibrillation of alpha-synuclein.
    Fink AL
    Acc Chem Res; 2006 Sep; 39(9):628-34. PubMed ID: 16981679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fine epitope mapping of monoclonal antibodies specific to human alpha-synuclein.
    Choi JY; Park HJ; Seong YM; Choi EY; Min BR; Rhim H
    Neurosci Lett; 2006 Apr 10-17; 397(1-2):53-8. PubMed ID: 16380207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.